期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱![]() | Experimental Hematology & Oncology LetPub Score 6.0
50 ratings
Rate
Reputation 7.2 Influence 4.9 Speed 7.1 | ||||||||||||||||||||||||
期刊簡稱 | EXP HEMATOL ONCOL | ||||||||||||||||||||||||
ISSN | 2162-3619 | ||||||||||||||||||||||||
h-index | N.A. | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 6.40%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | https://www.springer.com/journal/40164 | ||||||||||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/EXHO | ||||||||||||||||||||||||
開放訪問 | Yes | ||||||||||||||||||||||||
出版商 | BioMed Central | ||||||||||||||||||||||||
主題領域 | Medicine | ||||||||||||||||||||||||
出版國/地區 | ENGLAND | ||||||||||||||||||||||||
發行頻率 | |||||||||||||||||||||||||
創刊年 | 2012 | ||||||||||||||||||||||||
每年文章數 | 71每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 100.00% | ||||||||||||||||||||||||
OA Related Info![]() | APC: Yes( GBP2490; USD3190; EUR2790; ) APC waiver:Check Notes Other charges: No Keywords: haematology、oncology Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2162-3619%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 6 Weeks | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[Experimental Hematology & Oncology] 的評論 | 撰寫評論 |
作者: PanchoZ 領域: 医学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2025-02-23 10:38:52 評論於 After being rejected by editor Liu Delong, JHO switched to EHO and submitted to a collection that happened to be available at that time. However, the article remained stagnant in the hands of the responsible editor of that collection for over a month. After sending an inquiry letter, the article finally landed in the hands of editor Liu Delong, who showed extremely high efficiency. Kudos to Liu for his quick response! ![]() ![]() |
作者: PanchoZ 領域: 医学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2025-02-23 10:35:30 評論於 Here are the submission deadlines for JHO and EHO: JHO submitted first. ![]() ![]() |
作者: PanchoZ 領域: 医学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2025-02-23 10:33:11 評論於 Just received a paper, which was transferred to me after being rejected by the sister journal JHO for review. After the transfer, it was not reviewed, but I was asked to supplement according to the dozens of opinions given by the 4 reviewers of JHO. After working hard to complete the supplement, it was sent back and another reviewer was found, who provided some additional opinions. After completing another round of supplements, it was sent back and accepted after a minor formatting revision. Overall, the quality of articles in this journal is uneven, with some good quality articles, but also some obvious cases of favoritism leading to poor reputation of the journal. The journal's speed is relatively fast, and in a rush to graduate, I agreed to transfer to EHO. To be honest, it was a bit of a loss to follow the dozens of review opinions from JHO and publish in EHO, but looking at the rising impact factor of the sister journal JHO, it is likely that this journal will also rise. Hopefully the journal will continue to improve, while publishing fewer low-quality articles! ![]() ![]() |
作者: 萧赢 領域: 医学 審稿時間: 2.0 month(s) 結果: 修改後接受 撰寫評論 |
2022-09-02 20:48:47 評論於 5-18 Submission 6-3 Resubmission after format modification 6-8 Reviewer's comment 8-9 Revision 8-12 Resubmission 8-13 Reviewer's comment 8-26 Major revision 8-27 Resubmission 8-29 Invite another reviewer 8-30 Reviewer's comment 8-30 Minor revision 8-31 Resubmission again 9-2 Acceptance ![]() ![]() |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us